Drug Profile
Research programme: AAV vector gene therapy - Cell Genesys
Latest Information Update: 12 Oct 2006
Price :
$50
*
At a glance
- Originator Cell Genesys
- Class
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Brain cancer in USA (unspecified route)
- 17 Jun 2003 Preclinical trials in Brain cancer in USA (unspecified route)